Network pharmacology screened 15 key alkaloid components (e.g., dihydrochelerythrine, magnoflorine, etc.)and 24 core targets (e.g., SRC, STAT3, MAPK3) and confirmed their strong binding activities by molecular docking, suggesting that ARSHs can exert anti-RA effects by modulating immune-inflammation-related pathways. Here, MAPK3 is linked to rheumatoid arthritis.